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Abstract A low degree of amino acid sequence similarity to 
FK506-binding proteins (FKBPs) has been obtained for the 
peptidyl prolyl cisltrans isomerase (PPIase) domain of E. coli 
trigger factor (TF) that was thought to be significant with regard 
to the enzymatic properties of the bacterial enzyme. We 
examined whether the alteration of a negatively charged side-
chain at position 37 (FKBP numbering) and a phenylalanine at 
position 99, both highly conserved through both types of 
enzymes, leads to parallel effects on the catalytic activity of 
both FKBP 12 and TF-PPIase domain in a series of tetrapeptide 
substrates with different Pi subsites. For the latter enzyme, 
substitution of Glu178 by Val or Lys, which aligns to Asp in 
human FKBP12, enhanced the PPIase activity, whereas a 
strongly decreased enzymatic activity was determined for the 
Asp3Xeu and Asp37Val variants of FKBP12. Regardless of the 
Pi subsite of the substrate used for the assay, mutation of 
Phe233Tyr generated a protein variant of the TF-PPIase domain 
with about 1% of the wild type PPIase activity. Dependent on the 
substrate nature, a moderate decrease as well as a 4.8-fold 
increase in kcsJKm could be determined for the corresponding 
Phe"Tyr FKBP12 variant. Neither of the mutations of the TF-
PPIase domain was able to implant FK506 inhibition found as a 
major characteristic of the FKBP family of PPIases. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The 48 kDa trigger factor (TF) of E. coli is an abundant 
cytosolic peptidyl prolyl cisltrans isomerase (EC 5.2.1.8) with 
a unique efficacy in catalyzing trans to eis prolyl bond isomer-
ization during the refolding of denatured proteins [1]. Its ex-
traordinary catalytic power results from the modular structure 
of TF. It functionally combines the central PPIase domain 
(TF-PPIase domain), which encompasses residues Gin148 to 
Thr249, with the C-terminal and N-terminal extensions pre-
senting chaperone-like properties toward unfolded protein 
substrates [2]. Interestingly, the protein was first described 
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as a molecular chaperone specifically involved in the secretion 
machinery of E. coli [3-5]. In the context of a possible role as 
a folding catalyst it is important to note that TF does not only 
represent a peripheral component of the 50S subunit of the E. 
coli ribosome [1,6], but was also found to associate with nas-
cent protein chains of the translating ribosome [7,8]. Appar-
ently involved in a different pathway TF was described to be 
an essential factor in the GroEL-stimulated proteolysis of 
misfolded proteins [9]. 
The E. coli TF-PPIase domain and human FKBP 12 share 
only 25.3% amino acid sequence identity [1]. However, the 
apparent relationship between TF-PPIase domains and the 
FKBP family of PPIases became more visible by hydrophobic 
cluster analysis, which revealed a hydrophobic binding pocket 
quite similar to that of FKBPs for the inhibitor FK506 [10]. 
Even if direct proof by three-dimensional structures of FKBP/ 
substrate complexes is still lacking, this pocket may be iden-
tical to the catalytic site. This point of view is supported, by 
analogy, considering the X-ray structures of complexes of 
human cytosolic cyclophilin (Cypl8). For this archetype of 
another PPIase family structural data of complexes with the 
tight binding inhibitor cyclosporin A [11] and with various 
substrates [12,13] exist. In the Michaelis complexes of sub-
strates the proline ring fits well into the MeVal11 position of 
the enzyme/inhibitor complex. For the FKBP-like PPIases the 
proposed similarity of the active site of FKBPs and TF-
PPIase domains is at variance with the lack of inhibition of 
the latter enzyme up to 20 (J.M concentrations of FK506 [14]. 
With respect to FK506 inhibition the full-length TF behaves 
similarly to its catalytic domain encompassing residues 145-
251 of the protein [14]. Thus, a functional relationship be-
tween both types of PPIases still remains an open question. 
Functional analyses of FKBP 12 variants engineered by site-
directed mutagenesis were reported allowing conclusions con-
cerning the major determinants for FK506 binding. Numer-
ous FKPB12 variants exhibit FK506 affinities in the same 
range as the wild type enzyme [15-18]. As exceptions, Asp37 
and Phe" have been identified as major determinants of both 
enzyme activity and tight binding of FK506 [18-20]. 
These observations indicate that mutational analysis of 
Asp37 and Phe" in conjunction with the mutations at the 
corresponding positions Glu178 and Phe233 in TF-PPIase do-
mains may reflect a possible functional relationship between 
TF and FKBPs. In this study we report results concerning 
functional properties of the active site using 6 different mutant 
TF-PPIase domains and the equivalent FKBP12 variants. We 
demonstrate differential effects of the mutations for both types 
of enzymes. None of the TF-PPIase domain variants could be 
inhibited by FK506. 
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2. Materials and methods 
2.1. Materials 
Restriction endonucleases and T4-DNA ligase were purchased from 
Boehringer Mannheim (Germany). T7-Sequencing Kit was from Phar-
macia Biotech (Freiburg, Germany). GeneCleanll Kit were obtained 
from BiolOl (Vista, California, USA). Sequencing grade [35S]dATP 
and [32P]dATP were purchased from ICN Pharmaceuticals GmbH 
(Meckenheim, Germany). PrimeZyme polymerase was from Biometra 
(Göttingen, Germany). Oligonucleotides were obtained from Euro-
gentec (Seraing, Belgium). Ni2+-NTA agarose and pQE30 were 
from Qiagen (Hilden, Germany). DNA molecular weight markers 
were from Gibco (Paisley, UK). Fractogels EMD DEAE-650(M) 
and EMD SOj~-650(M) were from Merck (Darmstadt, Germany). 
Protein molecular weight markers were obtained from Serva (Heidel-
berg, Germany). Agarose, buffers and media were purchased from 
Serva, Gibco, AppliChem (Darmstadt, Germany), Biomol (Hamburg, 
Germany) and Roth (Karlsruhe, Germany). The PPIase substrates 
(Suc-Ala-Xaa-Pro-Phe-NH-Np) were purchased from Bachem (Hei-
delberg, Germany). 
2.2. Molecular biology techniques 
The DNA sequence of the TF-PPIase domain was amplified using 
chromosomal DNA of the E. coli K12 strain DH5a and two primers 
corresponding to the 5' and the 3' regions of the fragment (5'-
CAGTCAGGATCCGATGACGATGACAAACGTAAACAGCAG-
GCGACCTGG-3' and 5'-TGACTGAAGCTTTTATTCTGCAGTC-
AGTTCCGGCAG-3'). The resulting PCR product (corresponding to 
residues Arg145-Glu251 of the trigger factor) was ligated into the vec-
tor pUC18 and transformed into E. coli DH5cc. Recombinants were 
screened by restriction analysis and controlled by sequencing accord-
ing to the procedure of the manufacturer. A positive clone designated 
as TTtig3 was used for mutagenesis. To express the wild type plasmid 
DNA of TTtig3 was digested with BamHl and Hindlll. The resulting 
fragment was extracted from agarose gel and ligated into pQE30. 
Resulting plasmids were transformed into the E. coli K12 strain 
M15(pREP4) and recombinants were screened by restriction analysis. 
After controlling sequences, a clone designated as TTtig4 was used for 
overexpression of the wild type TF-PPIase domain. 
The construction of mutant TF-PPIase domains was carried out 
using the overlap extension method according to published instruc-
tions [21] with three primers for all mutations (I: 5'-CGGCT-
CGTATGTTGTGTGGA-3'; II: 5'-TATACGCCTGTGAAATACC-
GCACAG-3'; III: 5'-CCGTCAGGGCGCGTCAGCGG-3'). The 
following primers were used for site-directed mutagenesis of the TF-
PPIase-active domain (Glu178 Asp: 5'-GACGGCGAAGAGTTC-
GATGGCGGTAAAGCGTCTG-3', Glu178Val: 5'-GACGGCGAA-
GAGTTCGTAGGCGGTAAAGCGTCTG-3', Glu178Lys: 5'-GAC-
GGCGAAGAGTTCAAAGGCGGTAAAGCGTCTG-3', Phe198His: 
5'-CGTATGATCCCGGGCCATGAAGACGGTATCAAAG-3', 
Phe198Trp : 5'-CGTATGATCCCGGGCTGGGAAGACGGTATCA-
AAG-3', Phe233Tyr: 5'-GGTAAAGCAGCGAAATACGCTATCA-
ACCTGAAG-3'). Primary PCR products were purified by prepara-
tive electrophoresis using the GeneCleanll Kit according to 
instructions of the manufacturer and 30 ng of each was used for the 
second PCR reaction. The secondary PCR products were purified by 
preparative electrophoresis, digested with BamHl and Hindlll and 
ligated into pUC18 after purification by phenol/chloroform extrac-
tion. After transformation recombinants were screened by restriction 
analysis and controlled by DNA sequencing. Insert DNA of positive 
clones was ligated into pQE30, transformed into E. coli M15/pREP4 
and controlled by sequencing. 
For expression of wild type FKBP12 the pUC derivative pFKBP6 
was used (kindly provided by Boehringer Mannheim, Germany). Mu-
tagenesis was carried out as described above for the TF-PPIase var-
iants. For construction of the Asp37Leu FKBP12 variant the primer 
5'-GAAGATGGAAAGAAATTTCTTTCCTCCCGGGACAGA-3' 
was used. The plasmid expressing the Phe"Tyr FKBP12 variant was a 
kind gift from G. Wiederrecht. 
2.3. Overexpression and purification of the proteins 
All expressed variants of the TF-PPIase domain contained an N-
terminal extension with the amino acid sequence: 
MRGS(H)6GS(D)4K- followed by the TF-PPIase domain sequence 
Arg145-Glu251 which included the respective point mutation. The pu-
185 
rification of the mutated variants followed the same procedure as 
described below for the wild type. 
For overexpression of the wild type TF-PPIase domain cells of the 
strain E. coli M15(pREP4/pTTtig4) were grown in 1 1 of 2XYT me-
dium at 37°C until an OD600 of 0.5 was reached. Then 2.5 mM IPTG 
was added and the cells were grown for 5 h. The cells were harvested 
by centrifugation (6000 Xg, 4°C, 15 min), resuspended in 50 mM 
phosphate buffer (pH 8.0), 0.3 M NaCl, 1 mM PMSF and passed 
through a French pressure cell from SLM Aminco (Buettelborn, Ger-
many). All the following procedures were carried out at 4°C. Cell 
debris were removed by ultracentrifugation at 95 000 X g for 40 min 
in a 45Ti rotor from Beckman (Palo Alto, CA, USA). The super-
natant was applied to a Ni2+-NTA column (1x2 cm) equilibrated 
in the same buffer. Material unspecifically bound to the matrix was 
removed with 50 mM phosphate buffer (pH 6.0), 0.3 M NaCl, 10% 
glycerol (v/v). Bound proteins were eluted with a gradient of 0-0.5 M 
imidazole (40 ml total). The imidazole was removed by dialysis 
against 30 mM Tris buffer (pH 8.0). Further purification of the en-
riched protein was achieved by gel filtration. Samples of 1 ml were 
applied to a Superdex75 16/60 HiLoad FPLC column from Pharmacia 
(Uppsala, Sweden) equilibrated with 0.01 M HEPES (pH 7.5), 0.15 M 
KC1, 0.015 M MgCl2. During all runs the flow rate was maintained at 
0.8 ml/min. The eluted TF-PPIase domain was homogeneous in the 
SDS-PAGE as was verified by Coomassie staining. 
Wild type FKBP12 and the Asp37 Leu variant contained the N-
terminal extension MTMITNSM(H)4(D)4K- flanked by the 108 ami-
no acid segment of FKBP12. Numbering of the mutational sites re-
ferred to mature FKBP12 consisting of 107 amino acids. The FKBP12 
variants were expressed in E. coli strain K12 DH5a. All His-tagged 
variants were purified as described for the TF-PPIase domain. The 
expressed Phe"Tyr variant of FKBP12 lacked an engineered N-ter-
minal extension. Therefore, the first step of purification was anion 
exchange chromatography on a Fractogel EMD DEAE-650(M) col-
umn (1.6X9 cm) equilibrated with 20 mM HEPES (pH 7.3). The 
supernatant of the ultracentrifugation step, which had been adjusted 
to the same buffer conditions, was loaded onto the column with a flow 
rate of 1.5 ml/min. The FKBP variant was found in the flow through 
fractions which were loaded onto a Fractogel EMD SO.j~-650(M) 
column (1x8 cm) equilibrated in 20 mM MES (pH 6.3). The protein 
was eluted with 100 ml of a 0-1 M KC1 gradient. Final purification 
was achieved by gel filtration as described above. The homogeneity of 
the proteins was verified by Coomassie staining following SDS-
PAGE. 
2.4. Protein analysis 
The purified proteins were desalted on the LC-10A reversed phase 
HPLC system from Shimadzu (Kyoto, Japan) using a Nucleosil 500-5 
C3-PPN column (125x4 mm, guard column 11x4 mm) from Ma-
cherey-Nagel (Diiren, Germany). The column was pre-equilibrated 
with 0.09% aqueous trifluoroacetic acid in 1% acetonitrile (v/v). The 
proteins were eluted with a gradient of 25-60% acetonitrile in 0.08% 
trifluoroacetic acid within 25 min at 40°C at a flow rate of 1 ml/min. 
Runs were monitored by UV/VIS absorbance at 215 nm and 280 nm. 
Electrospray mass spectra were obtained on a VG Bio-Q triple-
quadrupole mass spectrometer from Fisons Instruments (Manchester, 
UK) equipped with an electrospray ion source. 4 |xl of the sample 
solution was injected directly into the electrospray source via a loop 
injector at a solvent (acetonitrile:water 1:1 v/v, 1% formic acid) flow 
rate of 4 (j.l/min. Scanning was performed from mlz 500 to mlz 1400 in 
10 s and this mass scale was calibrated using horse heart myoglobin. 
MALDI-MS was performed on a REFLEX reflection-type time-of-
flight spectrometer from Bruker-Franzen Analytik (Bremen, Ger-
many). Ions formed by laser desorption at 337 nm (N2 laser) were 
recorded at an acceleration voltage of 28.5 kV in the linear mode. A 
saturated solution of sinapinic acid in acetonitrile :methanol: water 
3:2:5 (v/v) was used as a matrix. Spectra were calibrated with angio-
tensin II, insulin and cytochrome c as external standards. 
The molecular masses of the TF-PPIase variants were determined 
using ESI-MS. The theoretical and experimental values, respectively, 
are 13 833.7 and 13 834.3 ±7.08 Da for the wild type, 13 819.7 and 
13820.6±4.4 Da for the Glu178Asp variant, 13832.8 and 
13 833.0 ±3.3 Da for the Glu178Lys variant, 13 804.7 and 
13812.2±11.0 Da for the Glu178Val variant, 13872.7 and 
13873.3±3.3 Da for the Phe198Trp variant (11661.5 and 
11668.3110.0 Da for the truncated fragment), 13 823.7 and 
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13 834.8 ± 7.4 Da for the Phe198His variant (11 612.5 and 11 615.5 ± 9.3 
Da for the shorter fragment), 13 849.7 and 13 856.6 ±4.9 Da for the 
Phe233Tyr variant. 
In consideration of the lack of the N-terminal Met for the mature 
proteins, the molecular masses for the His-tagged wild type FKBP12 
and its Phe"Tyr variant were calculated as 13 865.9 Da and 11 835.1 
Da, respectively. These values are in accordance with the experimental 
data from MALDI-TOF-MS that revealed respective molecular 
masses of 13 867.6 Da and 11834 Da. In addition, the integrity of 
the Phe"Tyr FKBP12 variant was confirmed by ESI-MS revealing a 
value of 11 834.1 ± 3.8 Da. Using ESI-MS the molecular mass of the 
His-tagged Asp37Leu variant was determined to be 13 864.7 ±5.7 Da, 
which matched the sequence-derived value of 13 863.9 Da. Approxi-
mately 20% of the purified recombinant FKBP12 and its Asp37Leu 
variant were N-terminally acetylated. 
Besides mass spectroscopic analyses of the purified protein a tryptic 
digestion of the Phe"Tyr FKBP12 variant was performed. The pro-
tein sample (200 pmol) was pyridylethylated, desalted by HPLC and 
digested with trypsin in 0.1 M ammonium bicarbonate at an enzyme 
substrate ratio of 1:20 at room temperature overnight. Tryptic pep-
tides were separated by HPLC and analyzed by MALDI-MS using a 
saturated solution of a-cyano-4-hydroxycinnamic acid in acetone as 
matrix. The determined molecular masses of the generated peptides 
matched perfectly with calculated values. 
Circular dichroism was measured using the J-710 spectropolarime-
ter from JASCO (Tokyo, Japan). Far-UV CD measurements were 
carried out in a thermostatted 0.1 cm quartz cell using 0.01 M sodium 
phosphate (pH 7.0) at 25°C. The spectra were recorded 20 times and 
averaged. The protein concentrations for the different variants of the 
TF-PPIase domain were: wild type 10.2 uM, Glu178Asp 11.9 |iM, 
Glu178Val 10 uM, Glu178Lys 10.2 uM, Phe233Tyr 10.3 uM. The con-
centrations for the FKBP variants were: wild type 10.8 uM, Asp37Leu 
9.5 uM and Phe"Tyr 10.0 u.M. Data were analyzed using the software 
provided by the instrument manufacturer JASCO. 
Protein concentration was determined spectrophotometrically using 
the molar extinction coefficients at 280 nm (6970 M _ 1 cm - 1 for the 
wild type and the Glu178 variants of the TF-PPIase domain, 8250 M _ 1 
cm - 1 for the Phe233Tyr variant, 9530 M _ 1 cm - 1 for the wild type 
FKBP12 and the Asp37Leu variant and 10810 M"1 cm"1 for the 
Phe"Tyr FKBP 12 variant). All data were calculated from the amino 
acid composition according to the method of Gill and von Hippel 
[22]. 
2.5. PPIase assay and FK506 inhibition 
PPIase activity measurements and inhibitory studies were carried 
out using a slightly modified protease-coupled assay as described pre-
viously [1]. Inhibition by FK506 was assayed utilizing Suc-Ala-Phe-
Pro-Phe-NH-Np as substrate. Stock solutions of 6.2 mM FK506 were 
prepared in ethanol. Inhibition of the TF-PPIase domain variants was 
tested up to a final concentration of 24 uM of FK506 in the assay. 
This concentration resulted from 252-fold dilution of the inhibitor 
stock solution into the quartz cell. Reference values of enzyme activity 
were determined in the presence of an equivalent volume of ethanol. 
For determining the K\ values of the Asp37Leu and the Phe"Tyr 
variants of FKBP12 the FK506 concentrations ranged from 0 to 1.4 
uM. The data were fitted non-linearly to competitive tight binding 
equation [23]. 
2.6. Computer methods 
Pairwise sequence alignments were performed using the BestFit and 
Gap programs from the UWGCG (University of Wisconsin Genetics 
Computer Group) software package, version 8.1. The SWGAP-
PEP.CMP symbol comparison table was used. Gap creation penalty 
was set at 3, gap extension penalty was 0.1. Quality values were 
obtained as described in the manual of the BestFit program. Signifi-
cance of the alignment was evaluated by determining the average 
quality of 10 alignments to randomized sequences of the same length 
and composition [24-27]. 
3. Results 
3.1. Molecular cloning and isolation of FKBP 12 and 
TF-PPIase domain variants 
Our mutagenesis experiments with the TF-PPIase domain 
were guided by results of site-directed mutagenesis on 
FKBP12, providing information about residues being impor-
tant for the formation of a functional active site in FKBPs. 
Among the three positions selected for point mutations, only 
Phe" is conserved in the TF-PPIase domains, but Asp37 and 
Trp59 are conservatively replaced by Glu and Phe, respectively 
(Fig. 1). In order to allow reliable comparison of the kinetic 
constants measured here, mutated TF-PPIase domains as well 
as corresponding FKBP12 variants, Asp37Leu and Phe"Tyr, 
have been produced. 
The DNA sequence of the TF-PPIase domain was cloned 
into vectors pUC18 and pQE30 corresponding to the clones 
TTtig3 and TTtig4, respectively. The strain TTtig4 was used 
for overexpression of the wild type TF-PPIase domain that 
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Fig. 1. Partial sequence alignment of the PPIase domains of the enzymatically active TFs from E. coli [28] and B. subtilis (EMBL Z75208) with 
FKBP12 [29]. Asterisks mark residues of FKBP12 involved in FK506 binding [18,30-32]. Boxed residues are conserved between the E. coli TF, 
B. subtilis TF and FKBP12. The positions of residues mutated in the E. coli TF-PPIase domain are marked by arrows. 
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Fig. 2. Far-UV CD spectra of TF-PPIase domain variants and FKBP12 variants are shown as mean residue molecular ellipticity versus wave-
length. Spectra were recorded at 25°C in 10 mM sodium phosphate (pH 7.0) (for further details see Section 2.4). The individual mutant pro-
teins are designated as follows: ( ) wild type TF-PPIase domain, (— - ) Glu178Lys variant, (- • -) Phe233Tyr variant, ( ) wild type 
FKBP12, ( ) Asp37Leu variant and ( ) Phe"Tyr variant of FKBP12. The CD spectra of the Glu178Asp and Glu178Val variants of the TF-
PPIase domain were identical to the Glu178Lys spectrum. 
finally carried an N-terminal His-tag. About 50 mg of pure 
recombinant protein was produced from 1 liter of overexpres-
sion culture. A similar expression level and final yield of pu-
rified protein was achieved for all of the TF-PPIase domain 
variants. 
In contrast to the stability of the other mutated TF-PPIase 
domains the Phe198Trp and the Phe198His variants were found 
to be unstable. Thus, the protein fractions after Chromato-
graphie purification on Ni2+-NTA agarose of the Phe198Trp 
and Phe198His variants were contaminated with truncated pol-
ypeptide chains to about 5% and 20%, respectively, as was 
estimated by evaluation of Coomassie stained SDS-polyacryl-
amide gels or the peak areas of the HPLC profile. Despite 
addition of protease inhibitors like PMSF and TLCK, the 
proteins were cleaved at the Lys232-Phe233 site as determined 
by Edman degradation and MALDI mass spectrometry. In 
the course of the protein purification by gel filtration separa-
tion of the intact TF-PPIase domain variants from these en-
zyme fragments could not be achieved. 
The expressed wild type FKBP12 and its Asp37Leu variant 
bore a His-tag adjacent to the respective N-termini of the 
FKBP12 sequence, whereas the Phe99Tyr variant was devoid 
of such N-terminal extension. In its mature form the first 
methionine was found to be cleaved off as was proven by 
MALDI and ESI mass spectrometry (see Section 2.4). The 
amino acid sequences of all proteins used in this study were 
verified by combinations of mass spectrometry, tryptic diges-
tion and Edman degradation (see Section 2.4 for details). To 
clarify the extent to which the occurrence of the engineered N-
terminal segments would affect the enzymatic properties of the 
proteins, the enzymatic activity of both the His-tagged form 
and the mature wild type FKBP12, where the His-tag was 
removed by enterokinase cleavage, was determined. In the 
protease coupled PPIase assay using Suc-Ala-Leu-Pro-Phe-
NH-Np as substrate, there was no difference in the values 
of kcat/KM detectable (T. Zarnt, unpublished results). 
The similarity of the far-UV CD spectra of all FKBP12 
variants and mutated TF-PPIase domains with those of the 
respective wild type proteins revealed a lack of structural dis-
turbances relevant for the mutations (Fig. 2). Based on this 
information it becomes quite obvious that functional differ-
ences determined for the protein variants were not due to 
structural instabilities of the proteins. 
3.2. Enzymatic properties 
In contrast to an assay using a polypeptide as a substrate, 
the tetrapeptide-based PPIase assay revealed an enzymatic 
efficiency for the wild type TF-PPIase domain similar to the 
full-length TF [14]. Thus, basic features of the catalytic mech-
anism of TF, which is thought to be indicative of the con-
struction of the active site, are retained in the TF-PPIase 
domain. We utilized the second-order rate constants kcebt/Ku 
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of a series of tetrapeptide substrates modified in Pi position as 
well as inhibition of enzyme activity by FK506 to collect in-
formation about these catalytic events. 
All mutant proteins characterized here were enzymatically 
active in the tetrapeptide assay even if the Phe233Tyr TF-
PPIase domain displayed only a very weak catalytic action 
toward Suc-Ala-Glu-Pro-Phe-NH-Np (Table 1). For 
FKBP12 the mutations generally decreased kclAIKu with the 
exception of the Phe99Tyr variant when assayed with Suc-Ala-
Glu-Pro-Phe-NH-Np. In this case a 4.8-fold increase was 
noted when compared with the wild type FKBP12, however, 
on a low level of absolute activity (Table 1). 
The residue Glu178 of TF corresponds to Asp37 of FKBP12, 
which was shown by computer simulations to be involved in 
the binding of an oligopeptide substrate by hydrogen bonding 
[33]. In order to create an Asp at this position and to explore 
the importance of the negative charge for the catalytic site, 
Glu178 of the TF-PPIase domain was mutated to either Asp, 
Val or Lys. The replacement of Glu178 by Asp showed only 
little effect on PPIase activity. Moreover, it did not implant 
inhibition by FK506 to the TF-PPIase domain, which was 
tested up to an inhibitor concentration of 24 u.M. Both 
Glu178Val and Glu178 Lys mutations mostly led to an increase 
in catalytic efficiency for the corresponding enzymes, up to 
2.4-fold for the Glu178Lys mutant (Table 1). The pattern of 
catalytic specificity regarding to the Pi subsite exhibited minor 
alterations even if the charge of the side chain was reversed in 
the Glu178Lys mutant. 
The difference of the Glu178Val and Glu178Lys variants of 
TF-PPIase domain to the Asp37Leu FKBP12 variant was 
manifested by a decreased level of PPIase activity ranging 
from 3 to 6% of the wild type enzyme (Table 1). As an ex-
ception, Glu in the Pi position [34] of the substrate caused an 
elevated kcailKu, but on a very low level of absolute activity. 
This mutation also resulted in a 700-fold lower affinity to 
FK506 with a K\ value of 349 ± 26 nM when compared with 
the wild type ( ^ = 0.5 nM [35]). 
A gain of FK506 affinity should be anticipated for the 
replacement of the corresponding residue Phe198 of TF by 
Trp in the TF-PPIase domain, because the hydrophobicity 
of the binding pocket will be enhanced by this substitution. 
This hypothesis is in line with published data on FKBP12 that 
the more hydrophilic His residue in this position greatly dete-
riorates FK506 binding and PPIase activity in parallel [20]. 
We found that mutation of the Phe198 to either a Trp or a His 
residue rendered the TF-PPIase domain unstable, leading to 
partial degradation by proteases during the purification pro-
cedure. Therefore, the enzymatic activities of these protein 
variants were estimated using an enzyme fraction contami-
nated with partially degraded protein. Considering the pro-
teolytic sensitivity of the mutant proteins, the protease 
coupled PPIase assay was substituted by an alternative, non-
proteolytic method utilizing solvent jumps with Suc-Ala-Phe-
Pro-Phe-NH-Np as substrate [36]. The estimates gave 56% 
and < 0.2% of the wild type enzyme activity for the Phe198Trp 
and Phe198His mutant, respectively. The detection of the en-
zyme activity of the Phe198His variant required an enzyme 
concentration of 8 u\M in the assay. Thus, it cannot be ruled 
out that the very low enzymatic activity of the Phe198 His 
variant has been caused by a minor PPIase contamination 
of about 0.3%) in the Phe198His fraction. 
A close proximity of Phe99 to the pipecolinyl ring and the 
C9 keto oxygen of FK506 in FKBP12 along with unique 
conservation among the FKBPs and TFs has to be noted. 
Subtle alterations introduced by the Phe99Tyr (Phe233Tyr) mu-
tation produced stable protein variants, but influenced both 
kinds of enzymes differently. With the exception of the inert 
Suc-Ala-Glu-Pro-Phe-NH-Np, the TF-PPIase domain variant 
yielded 1.1 ±0.4% of the wild type activity when assayed with 
the series of substrates modified in the Pi position. Contrary 
to this finding, the FKBP12 variant affected the substrate 
specificity profile in a range between 480% and 5%> of the 
specificity constants for the wild type enzyme. Its binding 
affinity for FK506 ( ^ value 118 ±9 nM) was lowered 240-
fold as compared to the wild type protein. However, none of 
the TF-PPIase domain variants could be competitively inhib-
ited by 24 uM FK506. 
4. Discussion 
In this paper we have shown by examining enzymatic prop-
erties of point mutated protein variants of the TF-PPIase 
domain and FKBP12 that considerable differences exist for 
both types of PPIases. Inhibition by the peptidomacrolides 
FK506 and rapamycin are major characteristics of the 
FKBPs. The low degree of amino acid sequence conservation 
throughout this family of PPIases indicates a less stringent 
requirement for structural retention of the active site. Conse-
quently, studies by site-directed mutagenesis, which included 
many residues of the FK506-binding pocket, revealed that 
both FK506 affinity and PPIase activity are rather resistant 
to point mutations. In fact, an enzymatically inactive FKBP12 
variant with a proven structural integrity of the protein has 
not been reported so far. Strikingly, the FKBP-like TF cannot 
be inhibited by FK506 despite maintaining most of the critical 
hydrophobic residues forming the putative active site [10]. 
In consideration of the close proximity (<3 .9 A) of the 
indole ring of Trp59 to the C$, CY, C8 carbon edge of the 
pipecolinyl ring of the peptidomacrolides in the FK506/ 
FKBP12 complex, the replacement of Trp by Phe in TF 
Table 1 
Subsite specificity (kCB,t/Ku, m M
- 1 s_1) of the E. coli TF-PPIase domain variants and FKBP12 variants towards Suc-Ala-Xaa-Pro-Phe-NH-Np, 
measured in the protease coupled assay at 10°C in 35 mM HEPES (pH 7.5) 
Xaa TF-PPIase domain FKBP12 
Phe 
Leu 
Ala 
Lys 
Glu 
wild type 
1060 
650 
240 
250 
6.9 
Glu178 Asp 
950 
620 
230 
220 
9.5 
Glu17f 
1720 
970 
350 
130 
16 
;Val Glu17i 
2520 
1500 
470 
89 
42 
*Lys Phe233Tyr 
14 
10 
1.9 
1.6 
n.d. 
wild type 
780 
1240 
100 
58 
1.5 
Asp3' 
48 
66 
32 
1.8 
1.2 
Leu Phe"Tyr 
64 
64 
37 
6.9 
7.2 
n.d. : PPIase activity was not detectable up to a final enzyme concentration of 5 uM in the cuvette. 
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may be unfavorable for the formation of the FK506 binding 
pocket. For Cypl8, which represents the prototype of the 
cyclophilin family of PPIases, Trp121 was found to be very 
important for binding of cyclosporin A [37]. Consequently, 
the Phe/Trp substitution at position 121 has been shown to 
strengthen the CsA/Cypl8 greatly. However, we could not 
implant competitive inhibition by FK506 by a Phe198Trp re-
placement in the TF-PPIase domain. The Phe side chain at 
position 59 in FKBPs seems to be sufficient to provide strong 
hydrophobic contacts to FK506. For FKBP12.6, which al-
ready has this substitution in a wild type FKBP, FK506 bind-
ing was found to be affected to a limited extent only [38]. 
The highly conserved Asp37 of the FKBPs was identified 
experimentally as a major determinant for FK506 binding. 
Thus, the conservative replacement by Glu in TFs was 
thought to be another potential candidate for the explanation 
of the abolished FK506 affinity. There are two additional 
examples for a replacement of Asp by Glu at this position. 
They comprise the third FKBP-like domain of FKBP52 of the 
steroid receptor and an E. coli ORF (FKBP 16) [30]. Like the 
TF-PPIase domain both sequences have an exceptionally low 
overall similarity to other FKBPs. 
Principally, a Glu residue at position 178 does not impair 
important steps in catalysis, because the kcs,JKu values for the 
TF-PPIase domain and for FKBP12 were of the same order 
of magnitude (Table 1). Based on the assumption of a FKBP-
like structure of TF, the Glu178Asp TF-PPIase domain variant 
was designed with the idea to restore FK506 binding, and to 
add a functional link between FKBPs and TFs. However, the 
failure of the TF variant to be sensitive toward FK506 pro-
vides evidence for a distinct active site of TF and FKBPs. 
This point of view is supported by the different effects on 
the enzymatic activity produced by mutations of the Glu178 
residue. For the Asp37Leu FKBP12 variant, a reduction of 
kCB,JKu to 3-6% of the wild type value was determined for 
most tetrapeptide substrates used here. This observation 
agrees well with the reported data of 9% for the Asp37Val 
replacement [17]. In contrast, the considerable increase in cat-
alytic power of the Glu178Val TF-PPIase domain, which can 
be seen throughout the series of tetrapeptide substrates, does 
not indicate any significant contribution of the carboxylate 
group to the catalytic mechanism as has been suggested for 
FKBPs [33]. Even a positively charged side chain like in the 
Glu178Lys variant cannot deteriorate the active site of TF. 
Moreover, the specificity constants determined for the 
Phe"Tyr FKBP12 variant (Phe233Tyr in TF) do not support 
a conserved active site structure in both types of PPIases. A 
previous study of this FKBP 12 mutation reported complete 
loss of both PPIase activity and binding of a FK506 derivative 
[20]. In contrast, we determined a A"; value of 118 ±9 nM for 
the Phe"Tyr FKBP12 variant, which is reduced only 200-fold 
as compared to the wild type FK506 affinity. Within the series 
of tetrapeptide substrates at least 5% of wild type activity was 
found for this protein variant, but also an enhanced activity 
could be obtained. Obviously, the Pi subsite specificity of the 
enzyme is altered by this replacement. Only a few other 
FKBP12 mutations like Tyr82Phe, His87Leu and the Tyr26-
Phe/Tyr82Phe double mutant FKBP12 resulted in altered Pi 
subsite specificity [18]. In the Michaelis complex of FKBP12, 
Phe" is thought to make a hydrogen bond to the imide car-
bonyl group. The electronic state of this bond may provide an 
important contribution to the energetic state of the rotational 
barrier. Mutation of Phe to Tyr will maintain this interaction, 
but will allow for subtle alterations of the hydrogen bond 
energy and the spatial alignment of the substrate within the 
active site. Various catalytic factors, like transition state sta-
bilization by desolvation, enzyme-assisted substrate autocatal-
ysis and ground-state destabilization are believed to contrib-
ute to the catalytic machinery of FKBPs [33,39]. For example, 
rate enhancement for hydrophobic substrates will be espe-
cially susceptible to the desolvation component of catalysis. 
The substrate dependent variability of the Phe" Tyr enzyme 
variants activity may reflect the distinct influence of the point 
mutation on the individual components of the catalytic ma-
chinery. 
In this respect, the Phe233Tyr TF-PPIase domain behaves 
unlike the corresponding FKBP12 mutation. There is an in-
variantly strong reduction in catalytic activity for the 
Phe233Tyr TF-PPIase domain, even if charged side chains 
are present in position Pi of the substrates (Table 1). This 
indicates that the catalytic component, which is retained on 
a low level of activity in this protein variant, is not related to 
a mechanism of transition state stabilization sensitive to sub-
strate hydrophobicity. Besides of mechanistic aspects, the uni-
formly low activity of this protein variant makes it a suitable 
candidate for complementation experiments in order to assess 
the role of TF catalytic activity in cell function. 
Taken together the functional differences of the enzyme 
variants described above argue against the presence of a po-
tential FK506-binding pocket within the TF active site. 
Recently we were able to show that two E. coli proteins, 
SlyD and FKBP 16 (SipA), are indeed PPIases that cannot be 
inhibited by FK506. Originally, they were assigned by se-
quence comparison to belong to the FKBPs. As for the TF-
PPIase domain, only a small degree of sequence conservation 
relative to other FKBPs has been obtained (Hottenrott, Schu-
mann, Pliickthun, Fischer and Rahfeld, accepted). Unfortu-
nately, any detailed functional characterization, such as was 
provided for the TF-PPIase domain by the data presented 
above, does not yet exist for these enzymes. Do trigger factors 
along with other non-FK506-binding FKBPs make up a new 
family of PPIases? 
The alignment of the TF-PPIase domain with the PPIase 
domain of the FK506-inhibitable, Mip-like FKBP22 from E. 
coli revealed similarity and identity values of 55.4% and 
28.7%, respectively. Quality values for this alignment of 45 
and 49.4 exceed only by 10 and 14 the average quality values 
of 10 alignments to randomized sequences. Alignments of 
more closely related FKBPs, either SlyD with SlpA or 
FKBP12 with FKBP22, gave quality values of 89.7 and 
80.4. These numbers are higher by 40 and 46 than the average 
values of the randomized alignments. On the other hand, 
alignments of TF-PPIase domain with the PPIase domains 
of the non-FK506-binding SlyD and SlpA produced even low-
er similarities and identities, 48.9% (21.3% identity) and 53.6% 
(17.4% identity), respectively. Quality values of 49.5 and 44.6, 
higher by only 10 and 7 than the average values from random-
izations, were obtained for both alignments. Due to the very 
low level of sequence similarity, these data cannot assist in 
establishing a new PPIase family made up by non-FK506-
binding FKBPs and trigger factors. 
In conclusion, our functional data are indicative of an only 
limited relationship of the active sites of TF-PPIase domains 
and FK506-inhibitable FKBPs. To include these important 
190 
functional characteristics into the classification of PPIases, we 
suggest that TF-PPIase domains be defined as a subfamily of 
FKBPs . 
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